Active Ingredient(s): Glasdegib
FDA Approved: * November 21, 2018
Pharm Company: * PFIZER INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Daurismo Overview

Glasdegib, sold under the brand name Daurismo, is a medication for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults older than 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy.[3][4][5] It is taken by mouth and is used in combination with low-dose cytarabine.[4] The recommended dose of glasdegib is 100 mg orally once daily on days 1 to 28 in combination with cyt...

Read more Daurismo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glasdegib

Recent Daurismo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 100mg, 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Daurismo: (2 results)

Sorted by National Drug Code
  • 0069-0298 Daurismo 25 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
  • 0069-1531 Daurismo 100 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc

Other drugs which contain Glasdegib or a similar ingredient: (1 result)